Approved (57 companies)
Companies with at least one active program at Approved.
| Ticker | Company | Therapeutic areas | Approved programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics | Oncology | 1 | Approved | $172M | 5 |
| ADMA | Adma Biologics | ImmunologyInfectious Disease Rare | 3 | Approved | $3.02B | 4 |
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 3 | Approved | $1.79B | 7 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 3 | Approved | $111M | 10 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 2 | Approved | $1.36B | 9 |
| ARDX | Ardelyx | GI/HepatologyRenal | 2 | Approved | $799M | 4 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | $447M | 10 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $290M | 12 |
| AXSM | Axsome Therapeutics | Neurology Rare | 4 | Approved | $7.15B | 15 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 2 | Approved | $1.93B | 4 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | $74.0M | 5 |
| CRNX | Crinetics Pharmaceuticals | MetabolicOncology Rare | 1 | Approved | — | 6 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 1 | Approved | $253M | 8 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 10 | Approved | $1.84B | 17 |
| EXEL | Exelixis | CardiovascularOncology | 6 | Approved | $16.7B | 23 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 5 | Approved | $61.4M | 16 |
| GERN | Geron | Oncology | 1 | Approved | $644M | 3 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 4 | Approved | $1.94B | 17 |
| HROW | Harrow | Ophthalmology Rare | 9 | Approved | $1.11B | 15 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $6.66B | 17 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.44B | 12 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 5 | Approved | $26.7B | 15 |
| IVVD | Invivyd | Infectious Disease | 1 | Approved | $152M | 5 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 13 | Approved | $4.49B | 29 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $688M | 13 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | $3.12B | 17 |
| LENZ | LENZ Therapeutics | Ophthalmology | 1 | Approved | $110M | 1 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 3 | Approved | $5.11B | 9 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 1 | Approved | $1.54B | 5 |
| MIST | Milestone Pharmaceuticals | Cardiovascular | 1 | Approved | $51.4M | 2 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 1 | Approved | $109M | 11 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | $1.04B | 6 |
| IRD | Opus Genetics | Ophthalmology Rare | 2 | Approved | $391M | 12 |
| OTLK | Outlook Therapeutics | Ophthalmology | 1 | Approved | $87.9M | 3 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 2 | Approved | $8.14B | 12 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $3.64B | 4 |
| REPL | Replimune Group | Oncology | 1 | Approved | $1.87B | 5 |
| RVMD | Revolution Medicines | Oncology | 1 | Approved | $35.2B | 11 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 4 | Approved | $8.08B | 14 |
| RCKT | Rocket Pharmaceuticals | CardiovascularImmunology Rare | 1 | Approved | $236M | 4 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 4 | Approved | $1.58B | 11 |
| SCYX | Scynexis | Infectious DiseaseRenal Rare | 1 | Approved | $28.4M | 5 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 3 | Approved | $822M | 7 |
| TLX | Telix Pharmaceuticals | Oncology | 4 | Approved | $3.01B | 25 |
| TGTX | Tg Therapeutics | Neurology Rare | 1 | Approved | $9.48B | 6 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | 3 | Approved | $4.91B | 7 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularMetabolic+1 Rare | 7 | Approved | $1.70B | 10 |
| QURE | uniQure | HematologyMetabolic+1 Rare | 1 | Approved | $1.46B | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 8 | Approved | $230M | 27 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | 1 | Approved | $1.89B | 6 |
| VSTM | Verastem | Oncology | 1 | Approved | $934M | 5 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology Rare | 1 | Approved | $53.9M | 4 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | 1 | Approved | $3.41B | 7 |
| XFOR | X4 Pharmaceuticals | — | 1 | Approved | $316M | 2 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.59B | 28 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | 3 | Approved | $3.07B | 4 |
| ZYME | Zymeworks | OncologyRespiratory | 3 | Approved | $1.78B | 12 |
No companies match.